Stay updated on Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page.

Latest updates to the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page
- Check5 days agoChange DetectedA new publication citation was added to the publications list, referencing a 2026 Blood Advances article on infections in patients treated with daratumumab for newly diagnosed multiple myeloma. This addition provides contextual scholarly context without altering the study’s core information.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s UI/version marker was updated to **Revision: v3.5.3** and some related navigation/topic text from a prior revision was removed.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded 'Multiple myeloma' as a page topic and included a related topic link to MedlinePlus Genetics; updated the page revision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check41 days agoChange DetectedDeleted the disease term 'Multiple Myeloma' from the page and removed the Related Topic 'MedlinePlus Genetics'. This could reduce clarity about the study's focus and remove an external educational resource, while most other study content remains unchanged.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo vs Lenalidomide/Dex in Untreated Myeloma Clinical Trial page.